AI-enabled platform secures $121m to 'spearhead' NCE discovery, predictive pharmacology
Recursion Pharmaceuticals plans to partner with big pharma on rare disease programs after raising $121m to build out its machine learning-enabled platform, which draws on an in-house developed dataset to support drug discovery and development.